JPMorgan Chase & Co. reduced their target price on AtriCure from $47.00 to $39.00 and set an “overweight” rating on the stock in a report on Tuesday, April 28th.
Canaccord Genuity lifted their target price on AtriCure from $41.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, April 30th.
Oppenheimer boosted their price objective on AtriCure from $45.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th.
Finally, Needham & Company LLC reissued a “buy” rating and set a $49.00 price objective on shares of AtriCure in a research note on Friday, May 8th.
In other AtriCure news, Director Mark A. Collar sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st.